BMO Capital analyst Gary Nachman lowered the firm’s price target on Pacira to $52 from $60 and keeps a Market Perform rating on the shares. The company’s preliminary Q4 product revenue missed expectations, though this was not completely surprising given the October-November results previously provided, the analyst tells investors in a research note. Nachman adds that continued macroeconomic challenges and pricing pressure are weighing on growth despite Pacira indicating that volumes are outperforming flat surgical market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PCRX:
- Pacira price target lowered to $63 from $66 at Needham
- Pacira sees FY22 EPS ‘at least’ $2.50, consensus $2.77
- Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
- Pacira price target lowered to $50 from $54 at Cowen
- Pacira sinks after continuing to not provide outlook with monthly sales